脂蛋白檢測市場－策略分析與預測（2026-2031年）

預計脂蛋白檢測市場將以 8.7% 的複合年成長率成長，從 2026 年的 84.4 億美元成長到 2031 年的 178.9 億美元。

全球脂蛋白檢測市場正經歷顯著的變革，這主要得益於人們日益認知到先進脂質生物標記在心血管風險評估中的重要性。該市場涵蓋用於評估與脂質代謝和心血管疾病相關的脂蛋白生物標記的診斷檢測方法、實驗室設備、試劑和分析平台。市場檢測項目包括脂蛋白(a)、載脂蛋白AI、載脂蛋白B、脂蛋白顆粒分佈、補充傳統脂質譜分析的先進脂蛋白亞類。由於心血管疾病仍是全球主要死因之一，且僅靠傳統脂質檢測無法解釋所有心血管事件，因此市場需求持續成長。醫生正在尋求對不明原因心血管疾病、有明顯家族病史、遺傳性血脂異常症以及儘管接受他汀類藥物治療但仍存在持續心血管風險的患者進行先進的脂蛋白檢測。監管機構和專業學會也逐漸認知到某些脂蛋白生物標記的臨床意義，修訂後的指南也擴大推薦檢測脂蛋白(a)。為此，診斷公司正致力於擴大標準化檢測的普及範圍，推動自動化，並提高不同檢測平台間分析結果的一致性。隨著新型脂蛋白（A）標靶降血脂療法的研發不斷推進，該市場的策略重要性日益凸顯，診斷與治療之間的緊密聯繫也逐漸建立。

市場促進因素

臨床上對脂蛋白（a）作為心血管風險生物標記的認知日益提高

• 脂蛋白 (Lp) 檢測正逐漸成為心血管風險評估的重要組成部分，因為 Lp 水平升高會獨立增加動脈粥狀硬化性心血管疾病和主動脈瓣鈣化的風險。循環系統已將 Lp(a) 檢測納入對早發性心血管疾病和遺傳性血脂異常症患者的常規評估中。由於傳統的血脂檢測無法完全識別遺傳決定的心血管風險，因此越來越需要補充生物標記來改善患者分層。為此，診斷檢測實驗室正在擴展標準化 Lp(a)檢測法的範圍，以支援不斷發展的臨床實踐。提高醫生的認知將促進其在預防心臟病學領域的長期應用。

精準心血管醫學的擴展

• 在精準醫療領域，基於生物標記的治療決策正日益取代統一的治療策略。由於即使是膽固醇水平相似的患者，其個別心血管風險也存在顯著差異，因此醫療專業人員越來越需要進行全面的脂蛋白譜分析。製藥公司正在開發針對特定脂蛋白路徑的療法，這進一步增強了對精準臨床檢測在患者識別和後續觀察的依賴性。診斷與治療的整合正在改善個人化疾病管理，同時也支持市場的持續成長。

心血管疾病負擔加重

• 心血管疾病仍然是全球公共衛生面臨的重大挑戰，因此對更先進診斷技術的需求持續成長。醫療衛生系統優先考慮早期識別高風險族群，以減輕長期疾病負擔和降低醫療成本。雖然傳統的血脂篩檢可以識別出許多高風險患者，但它無法捕捉到與遺傳性脂蛋白異常相關的殘餘心血管風險。因此，先進的脂蛋白檢測透過支持早期療育和有針對性的預防策略，提供了額外的臨床價值。

脂蛋白分析的技術進步

• 最新的分析技術正在提高高級脂質檢測的準確性和可重複性。診斷設備製造商正在採用高度自動化的免疫檢測、基於核磁共振的顆粒分析以及高靈敏度檢測平台，從而降低檢查室間的差異。簡化的工作流程使得在不影響分析品質的前提下，能夠處理更多檢測項目。持續的創新提高了檢查室的可靠性，同時也推動了這些技術在臨床環境中更廣泛的應用。

市場限制因素

• 儘管臨床證據日益增多，但由於部分醫療機構對高級脂蛋白檢測的醫療覆蓋範圍有限，限制了其常規應用。某些高階脂蛋白生物標記的檢測方法缺乏統一標準，導致不同檢查室對檢測結果的解讀有差異。除了循環系統專家外，其他醫生對這些檢測的認知程度參差不齊，限制一般醫護人員對這些檢測的使用。此外，解讀高階脂蛋白譜的複雜性對一些臨床醫生來說也具有挑戰性。

目錄

第1章執行摘要

• 市場概述
• 主要分析結果
• 分析師意見
• 策略建議

第2章 分析方法

• 分析設計
• 資料收集和分析方法
• 市場規模估算
• 預測模型
• 先決條件和限制

第3章：脂蛋白檢測市場：概述、市場規模與預測

• 市場定義和範圍
• 行業概覽
• 產業變化
• 主要市場趨勢
• 過往市場分析
• 市場預測
• 脂蛋白檢測工作流程分析
• 心血管風險評估的現狀
• 臨床實驗室和照護現場檢測（PoC）實施情況分析。
• 預防醫學和大規模篩檢的發展趨勢
• 高階脂質生物標記檢測分析

第4章 市場動態

• 市場促進因素
• 市場限制因素
• 市場機遇
• 市場挑戰

第5章 行業情勢

• 產業價值鏈分析
• 定價分析
• 診斷生態系分析
• 報銷和醫療保險覆蓋範圍分析

第6章：創新趨勢

• 新興技術
• 高階脂蛋白顆粒分析
• 人工智慧在心血管風險評估的應用
• 臨床檢測領域的自動化
• 即時檢測脂蛋白檢測技術的創新
• 數位健康和​​遠端心血管監測

第7章 監理情勢

• 法律規範
• 檢查室認證標準
• 診斷品質和臨床實踐指南

第8章：脂蛋白檢測市場：展望分析

• 分析：按測試類型
• 分析：按技術
• 分析：按最終用戶

第9章：脂蛋白檢測市場：細分市場分析

• 按測試類型
  • 高密度脂蛋白膽固醇檢測
  • 低密度脂蛋白膽固醇檢測
  • 總膽固醇檢測
  • 三酸甘油酯測試
  • 脂蛋白(a) (Lp(a)) 檢測
  • 載脂蛋白檢測
  • 脂蛋白顆粒檢測
• 透過技術
  • 免疫測量
  • 酵素法
  • 核磁共振（NMR）波譜
  • 電泳
  • 層析法
• 最終用戶
  • 醫院
  • 診斷檢查室
  • 學術研究機構
  • 循環系統專科診所
  • 門診部

第10章：脂蛋白檢測市場：區域分析

• 北美洲
• 歐洲
• 亞太地區
• 南美洲
• 中東和非洲

第11章：脂蛋白檢測市場：國別分析

• 美國
• 加拿大
• 德國
• 英國
• 法國
• 義大利
• 西班牙
• 荷蘭
• 瑞士
• 中國
• 日本
• 印度
• 韓國
• 澳洲
• 巴西
• 沙烏地阿拉伯
• 南非

第12章 競爭格局

• 市佔率分析
• 策略趨勢
• 企業合併、商業夥伴關係和合作
• 產品發布和技術進步

第13章：公司簡介

• Abbott Laboratories
• F. Hoffmann-La Roche Ltd.
• Siemens Healthineers AG
• Beckman Coulter, Inc.（Danaher Corporation）
• Thermo Fisher Scientific Inc.
• Randox Laboratories Ltd.
• QuidelOrtho Corporation
• DiaSys Diagnostic Systems GmbH
• SEKISUI Diagnostics, LLC
• Diazyme Laboratories, Inc.
• Tosoh Corporation
• Mindray Medical International Limited
• Sysmex Corporation
• HORIBA, Ltd.
• Boston Heart Diagnostics Corporation

第14章：脂蛋白檢測市場：商業預測分析

第15章：投資與資金籌措分析

• 心血管診斷領域的投資
• 政府資助預防性篩檢項目
• 研發投資

第16章：未來展望

• 主要成長機遇
• 未來產業趨勢

The Lipoprotein Testing Market is forecast to grow at a CAGR of 8.7%, reaching USD 17.89 billion in 2031 from USD 8.44 billion in 2026.

The global lipoprotein testing market is undergoing significant evolution, driven by the growing recognition of advanced lipid biomarkers in cardiovascular risk assessment. This market comprises diagnostic assays, laboratory instruments, reagents, and analytical platforms designed to evaluate lipoprotein-associated biomarkers involved in lipid metabolism and cardiovascular disease. The market includes testing for lipoprotein(a), apolipoprotein A-I, apolipoprotein B, lipoprotein particle distribution, and advanced lipoprotein subclasses that complement conventional lipid profile measurements. Demand continues increasing because cardiovascular disease remains the leading cause of mortality worldwide, while conventional lipid measurements alone cannot explain all cardiovascular events. Physicians are requesting advanced lipoprotein testing for patients with unexplained cardiovascular disease, strong family history, inherited dyslipidemias, and persistent cardiovascular risk despite statin therapy. Regulatory organizations and professional societies are recognizing the clinical importance of selected lipoprotein biomarkers, with updated guidelines increasingly recommending lipoprotein(a) measurement. Diagnostic manufacturers are responding by expanding standardized assay availability, improving automation, and enhancing analytical consistency across laboratory platforms. The strategic significance of the market continues increasing alongside the development of novel lipid-lowering therapies targeting lipoprotein(a), creating a strong link between diagnostics and therapeutics.

Market Drivers

Growing Clinical Recognition of Lipoprotein(a) as a Cardiovascular Risk Biomarker

• Lipoprotein(a) testing is becoming an important component of cardiovascular risk assessment because elevated concentrations independently increase the likelihood of atherosclerotic cardiovascular disease and calcific aortic valve disease. Cardiologists are incorporating Lp(a) measurements into routine evaluation for patients with premature cardiovascular disease and inherited lipid disorders. Traditional lipid measurements do not fully identify genetically determined cardiovascular risk, creating demand for complementary biomarkers that improve patient stratification. Diagnostic laboratories are therefore expanding standardized Lp(a) assay availability to support evolving clinical practice. Greater physician awareness strengthens long-term utilization across preventive cardiology.

Expansion of Precision Cardiovascular Medicine

• Precision medicine increasingly relies on biomarker-guided therapeutic decisions rather than uniform treatment strategies. Healthcare providers are requesting comprehensive lipoprotein profiling because individualized cardiovascular risk varies significantly among patients with similar cholesterol levels. Pharmaceutical companies are developing therapies targeting specific lipoprotein pathways, increasing dependence on accurate laboratory testing for patient identification and monitoring. This integration between diagnostics and therapeutics supports sustained market expansion while improving personalized disease management.

Increasing Burden of Cardiovascular Disease

• Cardiovascular disease remains a major global public health challenge and continues driving demand for improved diagnostic approaches. Healthcare systems are emphasizing earlier identification of high-risk individuals to reduce long-term disease burden and healthcare expenditures. Conventional lipid screening identifies many patients at risk but does not capture residual cardiovascular risk associated with inherited lipoprotein abnormalities. Advanced lipoprotein testing therefore provides additional clinical value by supporting earlier intervention and targeted prevention strategies.

Technological Advancements in Lipoprotein Analysis

• Modern analytical technologies improve the precision and reproducibility of advanced lipid testing. Diagnostic manufacturers are introducing highly automated immunoassays, NMR-based particle analysis, and high-sensitivity laboratory platforms that reduce variability between laboratories. Improved workflow efficiency enables higher testing volumes without compromising analytical quality. Continued innovation strengthens laboratory confidence while supporting broader clinical implementation.

Market Restraints

• Limited reimbursement for advanced lipoprotein testing restricts routine adoption in several healthcare systems despite growing clinical evidence. Lack of universal assay standardization for certain advanced lipoprotein biomarkers creates variability in result interpretation across laboratories. Physician awareness remains inconsistent outside specialized cardiology practice, limiting testing utilization among general healthcare providers. Additionally, the complexity of interpreting advanced lipoprotein profiles can present challenges for some clinicians.

Technology and Segment Insights

By Test Type

• Lipoprotein(a) testing represents the fastest-growing segment because elevated Lp(a) concentrations are increasingly recognized as genetically determined risk factors for atherosclerotic cardiovascular disease and calcific aortic valve disease. Updated clinical guidelines are encouraging physicians to measure Lp(a) at least once in adulthood, particularly for patients with premature cardiovascular disease or strong family history. Laboratories are expanding standardized immunoassays to accommodate growing testing demand. Conventional lipid testing (HDL, LDL, total cholesterol, triglycerides) remains the foundation of cardiovascular risk assessment. Apolipoprotein testing provides additional insights into atherogenic particle concentration. Lipoprotein particle testing offers advanced characterization of lipid-related cardiovascular risk.

By Technology

• Immunoassays dominate the market because they provide standardized, automated, and high-throughput measurement of lipoprotein biomarkers suitable for routine clinical laboratories. Diagnostic manufacturers continue improving assay sensitivity and reproducibility while integrating testing into automated chemistry analyzers. Enzymatic assays are widely used for routine lipid panel testing. Nuclear Magnetic Resonance (NMR) spectroscopy enables detailed lipoprotein particle analysis. Electrophoresis and chromatography-based methods provide specialized characterization for research and advanced clinical applications.

By End User

• Hospitals account for a significant share of lipoprotein testing because they manage patients with established cardiovascular disease, inherited lipid disorders, and multiple cardiometabolic risk factors. Diagnostic laboratories are expanding advanced lipid testing capabilities to support preventive cardiology and precision medicine. Academic and research institutes contribute to biomarker discovery and clinical validation. Specialty cardiology clinics are increasingly utilizing advanced lipoprotein testing for high-risk patient management. Ambulatory care centers are adopting testing for preventive health programs.

Competitive and Strategic Outlook

• The competitive landscape features major diagnostic companies with strong clinical chemistry and immunodiagnostics portfolios. F. Hoffmann-La Roche Ltd. differentiates itself through its integrated diagnostics ecosystem combining clinical chemistry, immunodiagnostics, and digital laboratory solutions, leveraging its cobas analyzer portfolio. Abbott Laboratories maintains a strong presence through its Alinity and ARCHITECT platforms, focusing on automation and standardized analytical performance. Siemens Healthineers AG offers a comprehensive portfolio of clinical chemistry and immunoassay solutions, including the Atellica laboratory platform. Danaher Corporation (Beckman Coulter Diagnostics) provides automated clinical chemistry systems used extensively in hospital and reference laboratories. Thermo Fisher Scientific Inc. supports cardiovascular diagnostics through its life science technologies and analytical instrumentation. Randox Laboratories specializes in multiplex biomarker testing, including cardiovascular assays. Quest Diagnostics and Labcorp are major independent laboratory providers offering advanced lipoprotein testing services.
• Strategic developments include increasing integration of automation and digital platforms, expansion of standardized Lp(a) assays, and preparation for companion diagnostic applications with emerging lipid-lowering therapies. Companies are forming collaborations with pharmaceutical developers and healthcare providers to support therapeutic development and clinical adoption. Product launches focus on high-throughput immunoassays, NMR-based particle analysis, and integrated laboratory solutions. Companies that successfully combine analytical excellence, regulatory compliance, and global laboratory support are expected to maintain competitive leadership.

Conclusion

• The lipoprotein testing market is poised for significant growth, driven by the growing clinical recognition of lipoprotein(a) and other advanced biomarkers in cardiovascular risk assessment. The transition from conventional lipid profiling toward comprehensive risk stratification supported by advanced biomarkers and precision medicine is reshaping the market. Companies that successfully deliver standardized, automated, and clinically validated testing solutions are expected to lead the market. Ongoing therapeutic innovation, regulatory support, and expanding preventive healthcare initiatives will further accelerate adoption throughout the forecast period.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

• Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2031
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Snapshot
• 1.2 Key Findings
• 1.3 Analyst Insights
• 1.4 Strategic Recommendations

2. Research Methodology

• 2.1 Research Design
• 2.2 Data Collection Methodology
• 2.3 Market Size Estimation
• 2.4 Forecasting Model
• 2.5 Assumptions & Limitations

3. Lipoprotein Testing Market Overview, Size & Forecast

• 3.1 Market Definition & Scope
• 3.2 Industry Overview
• 3.3 Industry Evolution
• 3.4 Key Market Trends
• 3.5 Historical Market Analysis (2021-2025)
• 3.6 Market Forecast (2026-2031)
• 3.7 Lipoprotein Testing Workflow Analysis
• 3.8 Cardiovascular Risk Assessment Landscape
• 3.9 Laboratory & Point-of-Care Testing Adoption Analysis
• 3.10 Preventive Healthcare & Population Screening Trends
• 3.11 Advanced Lipid Biomarker Testing Analysis

4. Market Dynamics

• 4.1 Market Drivers
• 4.2 Market Restraints
• 4.3 Market Opportunities
• 4.4 Market Challenges

5. Industry Landscape

• 5.1 Industry Value Chain Analysis
• 5.2 Pricing Analysis
• 5.3 Diagnostic Ecosystem Analysis
• 5.4 Reimbursement & Healthcare Coverage Analysis

6. Innovation Landscape

• 6.1 Emerging Technologies
• 6.2 Advanced Lipoprotein Particle Analysis
• 6.3 Artificial Intelligence in Cardiovascular Risk Assessment
• 6.4 Automation in Clinical Laboratory Diagnostics
• 6.5 Point-of-Care Lipoprotein Testing Innovations
• 6.6 Digital Health & Remote Cardiovascular Monitoring

7. Regulatory Landscape

• 7.1 Regulatory Framework
• 7.2 Laboratory Accreditation Standards
• 7.3 Diagnostic Quality & Clinical Practice Guidelines

8. Lipoprotein Testing Market Landscape Analysis

• 8.1 Analysis by Test Type
• 8.2 Analysis by Technology
• 8.3 Analysis by End User

9. Lipoprotein Testing Market Segment Analysis (2021-2031)

• 9.1 By Test Type
  • 9.1.1 HDL Cholesterol Testing
  • 9.1.2 LDL Cholesterol Testing
  • 9.1.3 Total Cholesterol Testing
  • 9.1.4 Triglyceride Testing
  • 9.1.5 Lipoprotein (a) [Lp(a)] Testing
  • 9.1.6 Apolipoprotein Testing
  • 9.1.7 Lipoprotein Particle Testing
• 9.2 By Technology
  • 9.2.1 Immunoassays
  • 9.2.2 Enzymatic Assays
  • 9.2.3 Nuclear Magnetic Resonance (NMR) Spectroscopy
  • 9.2.4 Electrophoresis
  • 9.2.5 Chromatography-Based Methods
• 9.3 By End User
  • 9.3.1 Hospitals
  • 9.3.2 Diagnostic Laboratories
  • 9.3.3 Academic & Research Institutes
  • 9.3.4 Specialty Cardiology Clinics
  • 9.3.5 Ambulatory Care Centers

10. Lipoprotein Testing Market Geographical Analysis (2021-2031)

• 10.1 North America
• 10.2 Europe
• 10.3 Asia-Pacific
• 10.4 South America
• 10.5 Middle East & Africa

11. Lipoprotein Testing Market Country Analysis (2021-2031)

• 11.1 United States
• 11.2 Canada
• 11.3 Germany
• 11.4 United Kingdom
• 11.5 France
• 11.6 Italy
• 11.7 Spain
• 11.8 Netherlands
• 11.9 Switzerland
• 11.10 China
• 11.11 Japan
• 11.12 India
• 11.13 South Korea
• 11.14 Australia
• 11.15 Brazil
• 11.16 Saudi Arabia
• 11.17 South Africa

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Strategic Developments
• 12.3 Mergers & Acquisitions, Partnerships & Collaborations
• 12.4 Product Launches & Technology Advancements

13. Company Profiles

• 13.1 Abbott Laboratories
• 13.2 F. Hoffmann-La Roche Ltd.
• 13.3 Siemens Healthineers AG
• 13.4 Beckman Coulter, Inc. (Danaher Corporation)
• 13.5 Thermo Fisher Scientific Inc.
• 13.6 Randox Laboratories Ltd.
• 13.7 QuidelOrtho Corporation
• 13.8 DiaSys Diagnostic Systems GmbH
• 13.9 SEKISUI Diagnostics, LLC
• 13.10 Diazyme Laboratories, Inc.
• 13.11 Tosoh Corporation
• 13.12 Mindray Medical International Limited
• 13.13 Sysmex Corporation
• 13.14 HORIBA, Ltd.
• 13.15 Boston Heart Diagnostics Corporation

14. Lipoprotein Testing Market Commercial Forecast Analysis

• 14.1 Conventional Lipid Profile Testing
• 14.2 Lipoprotein (a) [Lp(a)] Testing
• 14.3 Advanced Lipoprotein Particle Testing
• 14.4 Apolipoprotein Testing Services
• 14.5 Point-of-Care Lipoprotein Testing Solutions
• 14.6 Automated Laboratory Lipoprotein Testing Systems
• 14.7 AI-Enabled Cardiovascular Risk Assessment Platforms

15. Investment & Funding Analysis

• 15.1 Investments in Cardiovascular Diagnostics
• 15.2 Government Funding for Preventive Screening Programs
• 15.3 Research & Development Investments

16. Future Outlook

• 16.1 Key Growth Opportunities
• 16.2 Future Industry Trends